These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9350751)

  • 21. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.
    Krishnarao TV; Galgiani JN
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1957-60. PubMed ID: 9303393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.
    Espinel-Ingroff A; Kish CW; Kerkering TM; Fromtling RA; Bartizal K; Galgiani JN; Villareal K; Pfaller MA; Gerarden T; Rinaldi MG
    J Clin Microbiol; 1992 Dec; 30(12):3138-45. PubMed ID: 1452697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of 80% inhibition standards for the determination of fluconazole minimum inhibitory concentrations in three laboratories.
    Espinel-Ingroff A; Steele-Moore L; Galgiani JN
    Diagn Microbiol Infect Dis; 1994 Oct; 20(2):81-6. PubMed ID: 7867309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of three antifungal susceptibility testing methods for the in vitro testing of Candida isolates from patients with HIV infection].
    Ruhnke M; Schmidt-Westhausen A; Trautmann M
    Mycoses; 1996; 39 Suppl 2():47-50. PubMed ID: 9198745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2862-4. PubMed ID: 11557481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media.
    Pfaller MA; Messer SA; Karlsson A; Bolmström A
    J Clin Microbiol; 1998 Sep; 36(9):2586-9. PubMed ID: 9705397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.
    Aller AI; Claro R; Castro C; Serrano C; Colom MF; Martín-Mazuelos E
    Chemotherapy; 2007; 53(4):300-5. PubMed ID: 17496416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans.
    Barchiesi F; Del Poeta M; Morbiducci V; Ancarani F; Scalise G
    Mycopathologia; 1993 Oct; 124(1):19-25. PubMed ID: 8159215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E-test and semiautomated broth microdilution test.
    van Eldere J; Joosten L; Verhaeghe V; Surmont I
    J Clin Microbiol; 1996 Apr; 34(4):842-7. PubMed ID: 8815094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study.
    Anaissie EJ; Paetznick VL; Ensign LG; Espinel-Ingroff A; Galgiani JN; Hitchcock CA; LaRocco M; Patterson T; Pfaller MA; Rex JH; Rinaldi MG
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2387-91. PubMed ID: 8891149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative evaluation of Etest and broth microdilution methods for fluconazole and itraconazole susceptibility testing of Candida spp.
    Martín-Mazuelos E; Gutiérrez MJ; Aller AI; Bernal S; Martínez MA; Montero O; Quindós G
    J Antimicrob Chemother; 1999 Apr; 43(4):477-81. PubMed ID: 10350375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative evaluation of PASCO and national committee for clinical laboratory standards M27-A broth microdilution methods for antifungal drug susceptibility testing of yeasts.
    Arthington-Skaggs BA; Motley M; Warnock DW; Morrison CJ
    J Clin Microbiol; 2000 Jun; 38(6):2254-60. PubMed ID: 10834985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative evaluation of National Committee for Clinical Laboratory Standards broth macrodilution and agar dilution screening methods for testing fluconazole susceptibility of Cryptococcus neoformans.
    Kirkpatrick WR; McAtee RK; Revankar SG; Fothergill AW; McCarthy DI; Rinaldi MG; Patterson TF
    J Clin Microbiol; 1998 May; 36(5):1330-2. PubMed ID: 9574699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of the minimum inhibitory concentration of Cryptococcus neoformans and Cryptococcus gattii against fluconazole by flow cytometry.
    Morales BP; Junior IN; Trilles L; Bertho AL; Oliveira Rde V; Nishikawa MM; Elias Mdos S; Wanke B; Lazéra Mdos S
    Med Mycol; 2014 Jan; 52(1):90-8. PubMed ID: 23808405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection.
    Aller AI; Martin-Mazuelos E; Lozano F; Gomez-Mateos J; Steele-Moore L; Holloway WJ; Gutiérrez MJ; Recio FJ; Espinel-Ingroff A
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1544-8. PubMed ID: 10817706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreasing fluconazole susceptibility of clinical South African Cryptococcus neoformans isolates over a decade.
    Naicker SD; Mpembe RS; Maphanga TG; Zulu TG; Desanto D; Wadula J; Mvelase N; Maluleka C; Reddy K; Dawood H; Maloba M; Govender NP;
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008137. PubMed ID: 32231354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Torulopsis glabrata: azole susceptibilities by microdilution colorimetric and macrodilution broth assays.
    Tiballi RN; Zarins LT; He X; Kauffman CA
    J Clin Microbiol; 1995 Oct; 33(10):2612-5. PubMed ID: 8567892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Turbidimetric and visual criteria for in vitro susceptibility testing of Cryptococcus neoformans clinical isolates.
    Del Poeta M; Barchiesi F; Arzeni D; Marinucci G; Scalise G
    Mycoses; 1994; 37(11-12):411-6. PubMed ID: 7659128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformans.
    Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
    Diagn Microbiol Infect Dis; 2004 Oct; 50(2):113-7. PubMed ID: 15474320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.